[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Iraj AK: Hodgkin's disease: assessment of treatment and survival rates in Iran. Asian Pac J Cancer Prev; 2004 Oct-Dec;5(4):379-82
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's disease: assessment of treatment and survival rates in Iran.
  • BACKGROUND AND OBJECTIVE: Each year an estimated of 7,500 new cases of Hodgkin's disease are reported in the United States.
  • It is a type of malignancy, where 75% of patients can recover and be cured with modern therapeutic approaches if presentation is in an early stage.
  • The main objective of this investigation was to assess the current situation with the disease in Iran, with determination of 5- and 10-year-survival rates.
  • The information obtained through medical files was organized and the rate of response to treatment and overall survival (OS) were computed.
  • The patient age (with a median of 31.8+/-17.1 years) did not show any effect on survival rate.
  • Mixed cellularity (47.2%) accounted for the most common histological subtype.
  • Complete remission was achieved with the ABVD chemotherapy regimen, included in 37.6% of overall chemotherapy regimens.
  • CONCLUSION: Chemotherapy was a significantly more effective treatment compared to other modalities, and provided complete remission in 52.7% of patients.
  • As general conclusions, early diagnosis, on time management of the patients, and use of appropriate treatment modalities provide significant prevention of mortality in Hodgkin's disease patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Hodgkin Disease / drug therapy. Hodgkin Disease / mortality
  • [MeSH-minor] Adult. Combined Modality Therapy. Cross-Sectional Studies. Disease-Free Survival. Female. Humans. Iran / epidemiology. Male. Retrospective Studies. Statistics, Nonparametric. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15546241.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


2. Milosević R, Colović M, Cemerikić-Martinović V, Colović N, Bogunović M: [Hodgkin's and Reed-Sternberg cells in the peripheral blood of a patient with advanced stage Hodgkin's disease]. Srp Arh Celok Lek; 2003 Sep-Oct;131(9-10):400-2
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin's and Reed-Sternberg cells in the peripheral blood of a patient with advanced stage Hodgkin's disease].
  • The occurrence of abnormal Hodgkin's and Reed-Sternberg cells in the peripheral blood in a patient suffering from Hodgkin's disease has been noticed exceptionally rare in a previous period, and especially rare in last ten years primarily due to successful treatment of this disease.
  • The analysis of mononuclear cells in rare patients with Hodgkin's disease was established that they belong to the B-lymphoid cells with expression of CD30 and CD15 antigens.
  • The examination of presence of Hodgkin's cells in the peripheral blood of patients with Hodgkin's disease is important for patients with advanced stage of the disease in which autologous stem cell transplantation and high dose chemotherapy is planned.
  • On histologic examination of lymph nodes, Hodgkin's disease, type nodular sclerosis with mixed cellularity was found.
  • The patient was in clinical stage IV/V of the disease and chemotherapy with 9 cycles of ABVD + Mp protocol was applied.
  • [MeSH-major] Hodgkin Disease / blood. Reed-Sternberg Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15058220.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Yugoslavia
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30
  •  go-up   go-down


3. Kulkarni A, Zlabek J, Farnen J, Capla R: Recurrent hypoglycemia and hypothermia in a patient with Hodgkin's disease. Haematologica; 2006 Dec;91(12 Suppl):ECR50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent hypoglycemia and hypothermia in a patient with Hodgkin's disease.
  • She subsequently developed nocturnal episodes of diaphoresis, confusion, and hypothermia.
  • Biopsy of periaortic lymph nodes revealed Hodgkin's disease of the mixed cellularity type.
  • Following chemotherapy, a complete remission ensued, the spells abated, and hypoglycemia was not induced by a 23-hour fast.
  • We believe that the patient's Hodgkin's disease was producing an insulin-like substance.
  • [MeSH-major] Hodgkin Disease / complications. Hypoglycemia / etiology. Hypothermia / etiology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / immunology. Bleomycin / administration & dosage. C-Peptide / analysis. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Insulin / blood. Middle Aged. Receptor, Insulin / immunology. Remission Induction. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Hypothermia.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17194656.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / C-Peptide; 0 / Insulin; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; EC 2.7.10.1 / Receptor, Insulin; ABVD protocol
  •  go-up   go-down


Advertisement
4. Khopkar U, Bhor U: Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy. Indian J Dermatol Venereol Leprol; 2008 Jul-Aug;74(4):379-82
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy.
  • Methotrexate (MTX) is used in the treatment of a variety of diseases such as rheumatoid arthritis, dermatomyositis, juvenile rheumatoid arthritis and chronic plaque psoriasis.
  • A 58-year-old male patient, a known case of psoriasis since 1994, had been receiving treatment with a low dose of MTX, 5 mg weekly for ten years intermittently (7-8 months/year).
  • He developed high-grade fever with cervical lymphadenopathy that was nonresponsive to routine line of management.
  • Lymph node biopsy revealed the presence of mixed cellularity type of Hodgkin's lymphoma.
  • The patient responded well to withdrawal of MTX and chemotherapy.
  • [MeSH-major] Dermatologic Agents / administration & dosage. Dermatologic Agents / adverse effects. Hodgkin Disease / chemically induced. Methotrexate / administration & dosage. Methotrexate / adverse effects. Psoriasis / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Humans. Injections, Intravenous. Male. Middle Aged. Remission Induction. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797063.001).
  • [ISSN] 0973-3922
  • [Journal-full-title] Indian journal of dermatology, venereology and leprology
  • [ISO-abbreviation] Indian J Dermatol Venereol Leprol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Dermatologic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Smolewski P, Robak T, Krykowski E, Blasiñska-Morawiec M, Niewiadomska H, Pluzanska A, Chmielowska E, Zambrano O: Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res; 2000 Mar;6(3):1150-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution.
  • On the basis of a retrospective study of 327 patients with Hodgkin's disease (HD), the prognostic significance of several factors, accepted previously and recently proposed, has been analyzed with regard to response to treatment and the survival time.
  • The only independent, pretreatment factors negatively influenced by either time of survival or response to treatment were the following: age at diagnosis of more than 45 years, advanced (IIIB/IV) clinical stage, poor clinical status according to Karnofsky's scale (score less than 70), presence of systemic symptoms, mixed cellularity/lymphocyte depletion histological type, multisite peripheral nodal localization of the disease, abdominal lymphadenopathy, and large primary tumor mass (bulky disease).
  • Short time to achieve complete remission (during the first four courses of chemotherapy) has proven to be significantly positive predictive factor.
  • Cumulative dose of cytostatics lower than programmed was a significantly negative prognostic factor that correlated with a shorter time of survival.
  • High activity of serum lactate dehydrogenase correlated moderately with poor response to the first-line treatment but did not influence the survival time.
  • Other clinical, morphological, and biochemical parameters influenced neither the prognosis nor the response to treatment.
  • High expression of proliferating cell nuclear antigen, p53, and BCL-2 correlated with poor response to the treatment and/or short time of survival.
  • [MeSH-major] Hodgkin Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proliferating Cell Nuclear Antigen / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Retrospective Studies. Survival Analysis. Treatment Outcome. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res 2000 May;6(5):2120
  • (PMID = 10741746.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


6. Wu SJ, Chen CY, Su IJ, Tang JL, Chou WC, Ko BS, Huang SY, Yao M, Tsay W, Chen YC, Wang CH, Tien HF: Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan. J Formos Med Assoc; 2008 Jan;107(1):4-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and treatment response of Hodgkin's lymphoma in Taiwan.
  • BACKGROUND/PURPOSE: Hodgkin's lymphoma (HL) is particularly rare in Asia, including Taiwan.
  • The report concerning its clinical features and treatment outcomes in Asians is limited.
  • The nodular sclerosis type (NS-HL) was the most common histopathologic subtype (45%), followed by mixed cellularity (29%), lymphocyte predominant (13%), and lymphocyte depleted subtype (2%).
  • Induction therapy led to complete remission (CR) in 87% of patients.
  • CONCLUSION: The treatment response of HL in Taiwan is good and comparable to that in Western countries.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18218572.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


7. Miyata A, Kojima K, Yoshino T, Fujii S, Shinagawa K, Ichimura K: Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia. Int J Hematol; 2001 Feb;73(2):230-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent Hodgkin's disease (mixed cellularity type) and T-cell chronic lymphocytic leukemia/prolymphocytic leukemia.
  • This patient simultaneously developed classic Hodgkin's disease (HD), a combination previously unreported.
  • A lymph node biopsy showed the histological features of HD (mixed cellularity) with infiltrating CD8+ lymphocytes, and immunohistochemical examination revealed the following phenotype of Reed-Sternberg cells: LeuM1/CD15+, BerH2/CD30+, L26/PanB-, UCHL-1/CD45RO-, cyCD3-, CD4, CD8-, CD20-, CD79a-, EMA-, EBER-1+, LMP-1+.
  • Although the HD was treated with chemotherapy that resulted in complete remission, the T-PLL/CLL took an indolent course.
  • [MeSH-major] Hodgkin Disease / complications. Leukemia, Prolymphocytic, T-Cell / complications


8. Audebert F, Schneidewind A, Hartmann P, Kullmann F, Schölmerich J: [Lymph node tuberculosis as primary manifestation of Hodgkin's disease]. Med Klin (Munich); 2006 Jun 15;101(6):500-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymph node tuberculosis as primary manifestation of Hodgkin's disease].
  • [Transliterated title] Lymphknotentuberkulose als Erstmanifestation eines Morbus Hodgkin.
  • FINDINGS: A contrast-enhanced CT scan of the neck, thorax and abdomen revealed a generalized enlargement of the cervical, axillar, mediastinal and retroperitoneal lymph nodes, multiple intrapulmonary nodular lesions with a diameter of up to 6 mm, and a substantial right-sided pleural effusion.
  • COURSE OF DISEASE: Under the assumption of reactivation of a lymph node tuberculosis, the patient was initially treated with an extended tuberculostatic therapy.
  • Because of disease progression another lymph node biopsy was performed revealing Hodgkin's disease of mixed-cellularity type with a partly histiocytic necrotizing, partly tuberculoid reaction.
  • Thereupon initiated chemotherapy according to the ABVD protocol led to a rapid amelioration of the clinical symptoms.
  • This consideration is particular important since Hodgkin's disease is typically associated with a cellular immunosuppression predisposing the subject to tuberculosis.
  • [MeSH-major] Hodgkin Disease / diagnosis. Tuberculosis, Lymph Node / diagnosis. Tuberculosis, Multidrug-Resistant / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antitubercular Agents / therapeutic use. Biopsy. Bleomycin / administration & dosage. Dacarbazine / administration & dosage. Diagnosis, Differential. Disease Progression. Doxorubicin / administration & dosage. Humans. Lymph Nodes / pathology. Recurrence. Tomography, X-Ray Computed. Vinblastine / administration & dosage

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16767573.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antitubercular Agents; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


9. Al-Ali HK, Wittekind C, Niederwieser D: [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]. Dtsch Med Wochenschr; 2007 Aug;132(33):1688-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
  • [Transliterated title] Komplette Remission eines rezidivierenden Hodgkin-Lymphoms vom Mischzelligen Typ nach Rituximab-Therapie.
  • INTRODUCTION: Cure rates of Hodgkin's disease (HD) with chemotherapy and/or radiotherapy are high.
  • However, a few patients are refractory to treatment or relapse.
  • We describe a patient with mixed cellularity (MC)-type HD with frequent relapses.
  • As all Hodgkin's or Hogan-Reed-Sternberg (HRS) cells expressed CD20, treatment with the anti-CD20 monoclonal antibody rituximab was given.
  • Biopsy revealed HD of MC type in stage IVA (Ann Arbor classification).
  • 4 months later, the disease progressed.
  • Despite treatment with gemcitabine there was no response.
  • RESULTS: Treatment was well tolerated.
  • A second treatment with rituximab yielded another complete remission which was maintained for 20 months.
  • In our patient the safety and efficacy of rituximab in relapsed CD20-positive classical HD of an MC type was demonstrated to achieve long-lasting remission.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Hodgkin Disease / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dacarbazine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Humans. Lymph Nodes / pathology. Male. Melphalan / therapeutic use. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prednisone / therapeutic use. Procarbazine / therapeutic use. Remission Induction / methods. Rituximab. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713864.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone; ABVD protocol; COPP protocol; Dexa-BEAM protocol
  •  go-up   go-down


10. Oliapuram Jose B, Koerner P, Bertolone S, Patel CC, Spanos WJ Jr, Paris KJ, Silverman CL, Yashar CM: Pediatric Hodgkin's disease. J Ky Med Assoc; 2004 Mar;102(3):104-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric Hodgkin's disease.
  • Twenty-five patients (78%) have nodular sclerosing type, 5 patients (16%) have mixed cellularity, and 2 patients (6%) have lymphocytic predominant type.
  • Eight patients (25%) were treated with radiation alone and 24 patients (75%) were treated with a combination of chemotherapy and radiation.
  • The treatment was given with 4 or 6 mv photon, and the median dose was 36 Gray (range 32-40 Gy).
  • The median irradiation dose in the combination group was 25 Gy (range 21 Gy-36 Gy).
  • All patients in Stages I and II are alive without any evidence of disease at the last follow-up.
  • One patient with Stage III disease developed a second cancer (PNET: primitive neuroectodermal tumor) 111 months after combination treatment and has died.
  • One Stage IV patient has died with Hodgkin's disease 28 months after treatment with combination therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Mechlorethamine / therapeutic use. Prednisone / therapeutic use. Procarbazine / therapeutic use. Vinblastine / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Remission Induction. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15067795.001).
  • [ISSN] 0023-0294
  • [Journal-full-title] The Journal of the Kentucky Medical Association
  • [ISO-abbreviation] J Ky Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  •  go-up   go-down


11. Greco M, Valsecchi M, Niccodemi C, Presas J, Corrado C, Winkel M: [Limphomatous meningitis as recurrence site in Hodgkin's disease]. Medicina (B Aires); 2006;66(4):332-4
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limphomatous meningitis as recurrence site in Hodgkin's disease].
  • [Transliterated title] Meningitis linfomatosa como sitio de recaída en la enfermedad de Hodgkin.
  • Intracraneal manifestations of Hodgkin's Disease (HD) are extremely rare, with an estimated incidence rate of approximately 0.5%.
  • 1) treatment-related leucoencephalopathy, 2) central nervous system infections, 3) paraneoplasic syndromes and 4) intracraneal lymphomas, which could be sub-classified into intraparenchymal or intradural masses.
  • We describe a case of a 40 year-old male with mixed cellularity type HD who developed neurological manifestations as relapsed disease.
  • The patient died from progressive disease refractory to third line chemotherapy.
  • We review the clinical features and differential diagnosis of leptomeningeal metastases in Hodgkin's disease.
  • [MeSH-major] Hodgkin Disease / pathology. Meningeal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dacarbazine / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Leukoencephalopathy, Progressive Multifocal / chemically induced. Leukoencephalopathy, Progressive Multifocal / pathology. Magnetic Resonance Imaging. Male. Paraneoplastic Syndromes / pathology. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977969.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; ABVD protocol; BEACOPP protocol; ESHAP regimen
  •  go-up   go-down


12. Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ: [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2008 Aug;30(8):630-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
  • OBJECTIVE: To compare the efficacy of chemotherapy alone, radiotherapy alone and combined-modality therapy in the treatment for early-stage Hodgkin's lymphoma (HL).
  • They were stratified into several groups based on initial treatment strategy: chemotherapy alone (CT group, n = 22), radiotherapy alone (RT group, n = 18), combined-modality therapy (CMT group, n = 109) and surgical resection (SR group, n = 1).
  • Chemotherapy regimens were mainly ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) and MOPP (mechlorethamine, vincristine, procarbazine and prednisone).
  • RESULTS: The pathological types included nodular sclerosis (NS, n = 84), mixed-cellularity (MC, n = 39), lymphocyte-predominant (LP, n = 23), lymphocyte-depleted (LD, n = 3) and nodular lymphocyte predominant Hodgkin's disease (NLPHD, n = 1).
  • There were 33 patients with complete response (CR), 109 with partial response (PR), 5 with stable disease (SD) and 3 with progressive disease (PD) after initial therapy.
  • The overall 7-yr survival rate was 89.3%, and treatment failure rate at 6 years was 18.8%.
  • The response rate of CMT group was superior to that of CT group, and the patients with nodular sclerosis or mixed-cellularity type had significantly lower risk of treatment failure (P = 0.009 and 0.019, respectively).
  • The multivariate analysis revealed that the treatment strategies affected the prognosis significantly.
  • The risk of failure of chemotherapy alone was 2.52 times higher than that of combined-modality therapy (P = 0.004).
  • CONCLUSION: Combined-modality therapy is more effective than chemotherapy alone or radiotherapy alone in the treatment for early stage Hodgkin's lymphoma.
  • Though its acute adverse effects are more severe than that of chemotherapy or radiotherapy alone, it may reduce the risk of treatment failure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Bleomycin / adverse effects. Bleomycin / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Dacarbazine / adverse effects. Dacarbazine / therapeutic use. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Mechlorethamine / adverse effects. Mechlorethamine / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / adverse effects. Prednisone / therapeutic use. Procarbazine / adverse effects. Procarbazine / therapeutic use. Proportional Hazards Models. Remission Induction. Retrospective Studies. Survival Rate. Vinblastine / adverse effects. Vinblastine / therapeutic use. Vincristine / adverse effects. Vincristine / therapeutic use. Young Adult


13. Msaad S, Yangui I, Ketata W, Ayoub A, Ayedi H: [Tracheal involvement revealing Hodgkin's disease. A case report]. Rev Pneumol Clin; 2007 Oct;63(5 Pt 1):323-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tracheal involvement revealing Hodgkin's disease. A case report].
  • [Transliterated title] Atteinte trachéale révélatrice d'une maladie de Hodgkin.
  • Inaugural tracheobronchitis is a rare but known manifestation of Hodgkin's disease.
  • Clinical signs are often misleading, retarding diagnosis and treatment.
  • We report a case of Hodgkin's disease revealed by wheezing with minimal hemoptysis.
  • Histology of the endoscopic biopsies demonstrated Hodgkin type infiltration of the trachea with mixed cellularity.
  • The patient was given chemotherapy and mediastinal radiotherapy and achieved complete remission.
  • [MeSH-major] Hodgkin Disease / diagnosis. Tracheal Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bleomycin / therapeutic use. Bronchoscopy. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Neoplasm Staging. Radiography, Thoracic. Radiotherapy Dosage. Remission Induction. Respiratory Sounds / etiology. Time Factors. Tomography, X-Ray Computed. Trachea / pathology. Vinblastine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166936.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; ABVD protocol
  •  go-up   go-down


14. Petera J, Macharová H, Pohanková R, Malír A, Coupek P, Konecný M, Patera J, Pecina J, Drbal J, Koukalová H, Vásová I: Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute. Neoplasma; 2000;47(2):129-32
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
  • Radiotherapy and chemotherapy, alone or in combination, are curative treatment methods in early stages of Hodgkin's disease (HD).
  • The choice of treatment depends on the stage of the disease, histological type and localization of the tumor, as well as on other prognostic factors.
  • 41 patients were diagnosed with Stage IA tumor, 1 patient with Stage IB, 75 patients with Stage IIA and 28 with Stage IIB disease.
  • The histological types of the disease were lymphocyte predominant in 23 patients, nodular sclerosis in 49 patients, mixed cellularity in 65 cases and lymphocyte depletion in 8 cases.
  • 39 patients were treated with combination of radiotherapy and chemotherapy.
  • 15 patients were given chemotherapy alone, 7 patients from this group experienced a relapse.
  • The five-year survival was 81% in patients with Stages IA and IIA disease, 65% in Stages IB and IIB disease.
  • Radiotherapy remains the curative method of choice in highly selected group of patients with early stages of Hodgkin's disease.
  • The results of radiotherapy alone are unsatisfactory in unselected clinical Stage I--II patients because of the presence of patients with adverse prognostic factors, particularly B symptomatology, mixed cellularity/lymphocyte depletion histology, higher age.
  • These patients are candidates for combined treatment.
  • Modern equipment and meticulous treatment are conditions crucial for the outcome of curative radiotherapy in patients with Hodgkin's disease.
  • Combination chemotherapy is very effective in the treatment of relapse following the primary radiotherapy.
  • [MeSH-major] Hodgkin Disease / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10985481.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] SLOVAKIA
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; COPP protocol; MOPP protocol; VBA protocol
  •  go-up   go-down


15. Saif MW, Hamilton JM, Allegra CJ: Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin's disease. Leuk Lymphoma; 2000 Oct;39(3-4):421-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Varicella zoster meningitis preceeded by thrombophlebitis in a patient with Hodgkin's disease.
  • Varicella zoster (V-Z) infections are common among patients with hematological malignancies, particularly Hodgkin's disease (HD).
  • Most of V-Z infections occur in patients with HD during the remission period, who have mixed cellularity sub-type, with stage III disease and who have received combined chemo-radiation therapy.
  • The authors describe a case of HD who developed V-Z meningitis preceeded by superficial thrombophlebitis of upper extremities during the period of active chemotherapy.
  • [MeSH-major] Hodgkin Disease / virology. Meningitis, Viral / chemically induced. Thrombophlebitis / virology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Herpes Zoster / chemically induced. Humans. Immunocompromised Host. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11342324.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Fujii H, Iwai T, Ueda Y, Nakagawa H: [Development of Hodgkin's disease four years after autologous peripheral blood stem cell transplantation for multiple myeloma]. Rinsho Ketsueki; 2000 Dec;41(12):1267-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Development of Hodgkin's disease four years after autologous peripheral blood stem cell transplantation for multiple myeloma].
  • We report a case of Hodgkin's disease that developed 4 years after autologous peripheral blood stem cell transplantation (PBSCT).
  • The patient, a 67-year-old Japanese male, underwent PBSCT for multiple myeloma (IgA-lambda type) under a conditioning regimen of carboplatin, etoposide and cyclophosphamide in June 1994 and obtained partial remission.
  • In December 1998, he noticed swelling of the left cervical lymph nodes, and Hodgkin's disease of the mixed cellularity subtype was diagnosed from a lymph node biopsy sample.
  • Immunohistochemistry studies showed that the Hodgkin's and Reed-Sternberg cells were CD30-positive.
  • After chemotherapy with MOPP and ABVD, the Hodgkin's disease was eradicated and the patient obtained complete remission in May 1999.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Hodgkin Disease / etiology. Multiple Myeloma / therapy
  • [MeSH-minor] Aged. Humans. Male. Time Factors. Transplantation, Autologous / adverse effects


17. Kondo H, Oyamada T, Mori A, Sumi H, Kurosu K, Kajii E, Mikata A: Direct-antiglobulin-test-negative immune haemolytic anaemia and thrombocytopenia in a patient with Hodgkin's disease. Acta Haematol; 2001;105(4):233-6
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Direct-antiglobulin-test-negative immune haemolytic anaemia and thrombocytopenia in a patient with Hodgkin's disease.
  • A case of direct-antiglobulin-test (DAT)-negative auto-immune haemolytic anaemia (AIHA) and immune thrombocytopenia (ITP) associated with Hodgkin's disease (HD) is reported.
  • The patient was DAT negative, although he exhibited the clinical features of warm-type AIHA and elevated levels of red-blood-cell-associated IgG (RBC-IgG).
  • A biopsy specimen of the inguinal lymph nodes showed HD of mixed cellularity.
  • Marked improvement of subjective symptoms, normalization of haematological values and a decrease in the level of both RBC- and PA-IgG were observed after the start of combination chemotherapy for HD.
  • [MeSH-major] Anemia, Hemolytic. Hodgkin Disease. Thrombocytopenia

  • Genetic Alliance. consumer health - Immune thrombocytopenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 S. Karger AG, Basel
  • (PMID = 11528097.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


18. Kochbati L, Chraïet N, Nasr C, Boussen H, Touati S, Ben Romdhane K, Maalej M: [Hodgkin disease of the nasopharynx: report of three cases]. Cancer Radiother; 2006 May;10(3):142-4
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hodgkin disease of the nasopharynx: report of three cases].
  • [Transliterated title] Maladie de Hodgkin du cavum: à propos de trois cas.
  • We report three cases of Hodgkin's disease (HD) involving the nasopharynx.
  • Their clinical presentations, morphological and immunohistochimical features and their therapy modalities are discussed.
  • Histological study showed mixed cellularity type of HD in all cases.
  • The treatment is based on radiotherapy that can be associated to neoadjuvant chemotherapy if nodes are involved.
  • [MeSH-major] Hodgkin Disease. Nasopharyngeal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309942.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. O'Toole O, O'Hare A, Grogan L, Bolger C, Brett FM: 20 year old lady with a paraspinal mass. Brain Pathol; 2010 May;20(3):683-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 20 year old lady with a paraspinal mass.
  • A 20 year old female presented with a 4 month history of right upper limb pain and paraesthesias.
  • The radiological features and recent rapid growth were felt to be in keeping with a large plexiform neurofibroma.
  • The patient underwent emergency resection of the lesion and pathology revealed Hodgkin's Lymphoma (HL)-mixed cellularity type.
  • The patient is currently undergoing treatment with ABVD chemotherapy.
  • CNS-HL is extremely rare and may occur de novo or in association with systemic disease.
  • Lesions may be parenchymal or dural based and are usually intracranial with an increased risk of CNS involvement in HL-mixed-cellularity type as in our patient.
  • [MeSH-major] Cervical Vertebrae / pathology. Hodgkin Disease / pathology. Spinal Canal / pathology. Spinal Cord Neoplasms / pathology. Spinal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20522095.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Singh A, Thapar V, Prabhu R, Naresh K, Joshi A, Supe A: Isolated splenic lymphoma: an elusive preoperative diagnosis. Indian J Gastroenterol; 2000 Oct-Dec;19(4):184-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was classical Hodgkin's lymphoma, mixed cellularity type (one case); marginal zone B-cell non-Hodgkin's lymphoma (one case); and large B cell type non-Hodgkin's lymphoma (two cases).
  • Mean follow up of these patients was 11 months; all patients received chemotherapy.
  • One patient died, of causes not related to the disease process.
  • [MeSH-major] Hodgkin Disease / diagnosis. Hodgkin Disease / surgery. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery. Splenic Diseases / diagnosis. Splenic Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intraoperative Period. Male. Middle Aged. Preoperative Care. Splenectomy / methods. Splenectomy / mortality. Splenomegaly / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Spleen Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11059187.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down






Advertisement